Clinical trial

Pembrolizumab + CVA21 in Advanced NSCLC

NCT02824965

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2017-08-09

PhasePHASE1

Study timeline

Study start (actual)2017-08-09Date precision: day

Registry last updated2021-07-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

CVA21BIOLOGICAL

Sponsors & collaborators

Olivia Newton-John Cancer Research Institutelead sponsor

Merck Sharp & Dohme LLCcollaborator

Viralyticscollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02824965 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.